TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.
Cbum's hair transplant is criticized for looking unnatural and not blending well, with some suggesting better results were expected given his resources. Discussions also cover the effects of steroids and finasteride on hair loss and muscle growth.
Hair loss treatments like finasteride and minoxidil are becoming more mainstream, with younger men starting early to prevent baldness. Increased sharing of transformations online and proactive approaches by Gen Z are contributing to noticeable changes.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
The post discusses using a combination of Dutasteride, Minoxidil, Ketoconazole, Estradiol, and Spironolactone for hair regrowth. Users suggest it needs more time and possibly a transplant, with some sharing personal experiences and side effects of similar treatments.
Minoxidil may cause wrinkles and dark circles, which some users report can be mitigated by adjusting dosage. Reactions vary, and while some dismiss these side effects, others experience significant changes.
A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
Transitioning genders humorously suggested for hair regrowth, noting some transgender individuals experience this. Discusses treatments like minoxidil, finasteride, and hormone therapy, but advises against transitioning solely for hair regrowth.
An 18-year-old is considering splitting 5mg Finasteride pills into 1.25mg doses to save money, but is concerned about potential hormonal fluctuations and side effects due to his age. Users advise caution, suggest consulting a doctor, and recommend considering lower or less frequent doses.
Dutasteride can cause hair shedding even with suppressed testosterone levels due to previous damage from DHT. Hair shedding is often a sign of damaged hair being replaced by healthier growth.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.
A 20-year-old male switched from MorrF5 to Zeelab’s MinoxilF, both containing minoxidil 5% and finasteride 0.1%, and is experiencing unexpected hair shedding. He is seeking guidance on whether the shedding is due to the brand change or if it's a normal reaction.
Gene editing for hair loss is not yet viable due to technological and economic challenges. Current treatments like Minoxidil, finasteride, and hair transplants remain the most practical options.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.
Switching from finasteride to dutasteride can cause significant hair shedding if done abruptly. It's recommended to overlap both treatments and gradually taper off finasteride to minimize shedding.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
A non-binary transfeminine person experienced significant hair regrowth after starting finasteride, minoxidil, microneedling, and hormone replacement therapy with estradiol. They encourage trans individuals concerned about hair loss to consider estrogen as it has greatly improved their hair condition.
The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.
A 20-year-old FTM individual started finasteride for hair loss with initial success but experienced increased shedding after 7 months. They are considering oral minoxidil as advised by their doctor to address the worsening hair loss.